We are live on ! Find out more
MTNB icon

Matinas BioPharma

18 hedge funds and large institutions have $1.97M invested in Matinas BioPharma in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more capital inflows, than outflows

Capital inflows: $5.12M | Capital outflows: $1.92M

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

10.8% more ownership

Funds ownership: 15.5% → 26.3% (+11%)

63% less funds holding

Funds holding: 48 → 18 (-30)

94% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 31

Holders
18
Holders Change
-30
Holders Change %
-62.5%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
5
Reduced
3
Closed
31
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

MTNB Hedge Fund Activity: Q3 2024 in Review

18 of the 6,991 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q3 2024, worth a combined $1.97M — down 68% from $6.15M a quarter earlier.

Sellers outnumbered buyers: 31 funds closed out of MTNB and 2 opened new positions — a net loss of 29 holders — while 3 trimmed existing stakes and 5 added.

The largest buyer was JTC Employer Solutions Trustee, adding an estimated $4.83M. The largest seller was Highbridge Capital Management, cutting an estimated $534K.

  • 18 institutional investors held Matinas BioPharma (MTNB) as of Q3 2024, down from 48 in Q2 2024.
  • Funds reported $1.97M of Matinas BioPharma stock for Q3 2024, down 68% quarter-over-quarter.
  • 2 funds opened new Matinas BioPharma positions in Q3 2024 and 31 closed out, a net change of -29 holders.
  • The largest Matinas BioPharma buyer in Q3 2024 was JTC Employer Solutions Trustee, an estimated $4.83M added.
  • The largest Matinas BioPharma seller in Q3 2024 was Highbridge Capital Management, an estimated $534K sold.

Based on aggregated 13F filings for Q3 2024.